Cargando…
Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients
OBJECTIVE: This study aimed to explore the cost-effectiveness of etanercept plus methotrexate (ETN+MTX) compared to triple disease-modifying anti-rheumatic drugs (DMARDs) in treating Chinese rheumatoid arthritis (RA) patients. METHODS: The 134 Chinese RA patients who were about to initiate ETN+MTX o...
Autores principales: | Shi, Zhi-Chao, Fei, Hong-Ping, Wang, Zhi-Liang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220444/ https://www.ncbi.nlm.nih.gov/pubmed/32011430 http://dx.doi.org/10.1097/MD.0000000000016635 |
Ejemplares similares
-
A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients
por: Tian, Feng, et al.
Publicado: (2019) -
Opsonic and Antibody Responses to Pneumococcal Polysaccharide in Rheumatoid Arthritis Patients Receiving Golimumab Plus Methotrexate
por: Migita, Kiyoshi, et al.
Publicado: (2015) -
Hepatic failure in a patient with rheumatoid arthritis treated with methotrexate: A case report
por: Miyata, Masayuki, et al.
Publicado: (2023) -
Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-α inhibitor
por: Lan, Joung-Liang, et al.
Publicado: (2017) -
Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis: An updated meta-analysis
por: Sun, Kai-jun, et al.
Publicado: (2021)